Background: The postmortem diagnosis of traumatic brain injury (TBI) remains challenging, particularly in rapidly fatal cases in which conventional histopathological alterations may be subtle or absent. Immunohistochemical biomarkers may improve the characterization of traumatic brain damage, although their diagnostic and survival-time-related significance remains incompletely established. Aim of the Study: To investigate a multimarker immunohistochemical panel in human postmortem brain tissue, identify TBI-related alterations, and explore their relationship with post-traumatic survival time. Materials and Methods: This observational pilot study included 36 autopsy subjects (19 fatal TBI cases and 17 non-traumatic controls). Formalin-fixed, paraffin-embedded corpus callosum sections were examined using conventional histology and immunohistochemistry for β-amyloid precursor protein (β-APP), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), cluster of differentiation 68 (CD68), transmembrane protein 119 (TMEM119), and glutathione peroxidase 4 (GPX4). Marker-specific quantitative and semiquantitative assessments were performed, followed by exploratory between-group comparisons with multiple-testing correction. Results and Discussion: Pathological β-APP-positive axonal lesions were identified in 89.5% of TBI cases versus 5.9% of controls. NfL immunostaining revealed more frequent focal swellings, varicosities, and bulbous profiles in TBI cases (median percentage of fields with morphological scores ≥3: 45% versus 0%). CD68/TMEM119 double immunostaining demonstrated significantly greater CD68 coexpression within the TMEM119-positive microglial population (median 93.12% versus 20.86%), suggesting an altered microglial immunophenotype. Glial GPX4 staining intensity was significantly lower in TBI cases (median score 1 versus 2), potentially reflecting altered antioxidant responses. GFAP morphological scores were descriptively higher in TBI cases, although neither these scores nor astrocyte density differed significantly between groups. The four significant marker-level comparisons remained significant after multiple-testing correction (all adjusted p < 0.01). Axonal and microglial abnormalities were detectable even after survival shorter than one hour, although no consistent temporal progression was identified. Conclusions: A multimarker immunohistochemical approach may complement conventional neuropathological examination by characterizing distinct axonal and glial alterations associated with fatal TBI, particularly in rapidly fatal cases. However, the diagnostic performance of the combined panel and its applicability to individual survival-time estimation require further validation in larger cohorts with more comprehensive anatomical sampling.
Background: The postmortem diagnosis of traumatic brain injury (TBI) remains challenging, particularly in rapidly fatal cases in which conventional histopathological alterations may be subtle or absent. Immunohistochemical biomarkers may improve the characterization of traumatic brain damage, although their diagnostic and survival-time-related significance remains incompletely established. Aim of the Study: To investigate a multimarker immunohistochemical panel in human postmortem brain tissue, identify TBI-related alterations, and explore their relationship with post-traumatic survival time. Materials and Methods: This observational pilot study included 36 autopsy subjects (19 fatal TBI cases and 17 non-traumatic controls). Formalin-fixed, paraffin-embedded corpus callosum sections were examined using conventional histology and immunohistochemistry for β-amyloid precursor protein (β-APP), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), cluster of differentiation 68 (CD68), transmembrane protein 119 (TMEM119), and glutathione peroxidase 4 (GPX4). Marker-specific quantitative and semiquantitative assessments were performed, followed by exploratory between-group comparisons with multiple-testing correction. Results and Discussion: Pathological β-APP-positive axonal lesions were identified in 89.5% of TBI cases versus 5.9% of controls. NfL immunostaining revealed more frequent focal swellings, varicosities, and bulbous profiles in TBI cases (median percentage of fields with morphological scores ≥3: 45% versus 0%). CD68/TMEM119 double immunostaining demonstrated significantly greater CD68 coexpression within the TMEM119-positive microglial population (median 93.12% versus 20.86%), suggesting an altered microglial immunophenotype. Glial GPX4 staining intensity was significantly lower in TBI cases (median score 1 versus 2), potentially reflecting altered antioxidant responses. GFAP morphological scores were descriptively higher in TBI cases, although neither these scores nor astrocyte density differed significantly between groups. The four significant marker-level comparisons remained significant after multiple-testing correction (all adjusted p < 0.01). Axonal and microglial abnormalities were detectable even after survival shorter than one hour, although no consistent temporal progression was identified. Conclusions: A multimarker immunohistochemical approach may complement conventional neuropathological examination by characterizing distinct axonal and glial alterations associated with fatal TBI, particularly in rapidly fatal cases. However, the diagnostic performance of the combined panel and its applicability to individual survival-time estimation require further validation in larger cohorts with more comprehensive anatomical sampling.
A Multimarker Immunohistochemical Investigation of Fatal Traumatic Brain Injury: Diagnostic Patterns and Survival-Time-Related Changes in Human Postmortem Brain Tissue—A Pilot Study
SECCO, LAURA
2024/2025
Abstract
Background: The postmortem diagnosis of traumatic brain injury (TBI) remains challenging, particularly in rapidly fatal cases in which conventional histopathological alterations may be subtle or absent. Immunohistochemical biomarkers may improve the characterization of traumatic brain damage, although their diagnostic and survival-time-related significance remains incompletely established. Aim of the Study: To investigate a multimarker immunohistochemical panel in human postmortem brain tissue, identify TBI-related alterations, and explore their relationship with post-traumatic survival time. Materials and Methods: This observational pilot study included 36 autopsy subjects (19 fatal TBI cases and 17 non-traumatic controls). Formalin-fixed, paraffin-embedded corpus callosum sections were examined using conventional histology and immunohistochemistry for β-amyloid precursor protein (β-APP), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), cluster of differentiation 68 (CD68), transmembrane protein 119 (TMEM119), and glutathione peroxidase 4 (GPX4). Marker-specific quantitative and semiquantitative assessments were performed, followed by exploratory between-group comparisons with multiple-testing correction. Results and Discussion: Pathological β-APP-positive axonal lesions were identified in 89.5% of TBI cases versus 5.9% of controls. NfL immunostaining revealed more frequent focal swellings, varicosities, and bulbous profiles in TBI cases (median percentage of fields with morphological scores ≥3: 45% versus 0%). CD68/TMEM119 double immunostaining demonstrated significantly greater CD68 coexpression within the TMEM119-positive microglial population (median 93.12% versus 20.86%), suggesting an altered microglial immunophenotype. Glial GPX4 staining intensity was significantly lower in TBI cases (median score 1 versus 2), potentially reflecting altered antioxidant responses. GFAP morphological scores were descriptively higher in TBI cases, although neither these scores nor astrocyte density differed significantly between groups. The four significant marker-level comparisons remained significant after multiple-testing correction (all adjusted p < 0.01). Axonal and microglial abnormalities were detectable even after survival shorter than one hour, although no consistent temporal progression was identified. Conclusions: A multimarker immunohistochemical approach may complement conventional neuropathological examination by characterizing distinct axonal and glial alterations associated with fatal TBI, particularly in rapidly fatal cases. However, the diagnostic performance of the combined panel and its applicability to individual survival-time estimation require further validation in larger cohorts with more comprehensive anatomical sampling.| File | Dimensione | Formato | |
|---|---|---|---|
|
Secco_Laura.pdf
Accesso riservato
Dimensione
30.96 MB
Formato
Adobe PDF
|
30.96 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/120066